High glycolysis levels in MSI-H CRC samples correlate with fewer infiltrating CD8+ T cells, suggesting that glycolysis may influence the efficacy of immune checkpoint inhibitor (ICI) therapy and could predict the prognosis of CRC patients undergoing immunotherapy (238). This evidence concerns the gene CD8A and colorectal carcinoma.